You are here

Aravive Receives Additional $2.6 Million Disbursement from the Cancer Prevention and Research Institute of Texas

HOUSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has received an additional $2.6 million disbursement from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant continues to support Aravive’s operations and on-going clinical development of AVB-S6-500.
Tuesday, February 19, 2019 - 07:00